Gregory Biedermann is an Oncology physician affiliated with University of Missouri. OpenAlex indexes 29 publications with 398 citations (h-index 8); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1705 E Broadway
Ste 100
Columbia, MO 652017166
Telephone
573-874-7800Provider last certified this registry record 31 Jan 2025.
Clinical trials
- Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer
Sponsor: University of Missouri-Columbia
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novocure Inc.Program year202513 payments
- GT Medical Technologies, IncProgram year20256 payments
- ABBVIE INC.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
38.7%Opioid Agonist13.7%Oxycodone Hcl100%Part D≥12 patientsBenzodiazepine9.5%Lorazepam100%Part D≥14 patients+ 2 more classes in this area
Genitourinary & hormones
38.1%alpha-Adrenergic Blocker38.1%Tamsulosin Hcl100%Part D≥18 patientsMetabolism & gastrointestinal
9.5%Caries prophylactic agents9.5%Sodium Fluoride100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- ENID: Phase II Trial of Definitive Chemoradiation with Elective Nodal Irradiation Dose De-Escalation for P16 Positive Squamous Cell Carcinoma of the Oropharynx
International Journal of Radiation Oncology*Biology*Physics
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Greg Flaker, MD
University of Missouri
Stephen Brietzke, MD
University of Missouri
Donald Doll, MD
University of Missouri
Christine Franzese, MD
University of Missouri
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”